We Develop Injectable & Topical Products
Kamat Pharmatech, founded in 2013, is a pharmaceutical development company based in Central New Jersey.
We are developing a portfolio of unique generic injectable and topical products.
We identify and pursue promising 505(b)(2) products backed by IP protection.
We serve as a Contract Development Organization.
We are actively seeking co-development and/or partnerships for all of the above.
Development of IV injectable formulations of insoluble and unstable compounds has been our forte since our inception. We can provide leadership in formulation development, process development, technology transfer, manufacture, and regulatory support.
We have technology to prepare suspensions and nano-suspensions such as fully equipped IKA homogenizers, quadro homogenizers, glenmill, as well as microfluidics processor. A full range of analytical techniques such as Shimadzu and Malvern particle size distribution (PSD) measuring systems can optimize these formulations to the desired target profile.
With extrusion capability, we can formulate liposomal and emulsion formulations efficiently. We have successly co-developed IV injectable products in this format for our clients.
With our analytical expertise and formulation capabilities, we can efficiently resolve Q1/Q2 sameness of almost any complex topical product.
We conduct diffusion, dissolution, rheometry, and Type 4 dialysis studies.
Our fully equipped laboratory includes the processing and analytical equipment for preparation as well as analysis of injectable formulations. The lists below outline some of our capabilities:
|HPLC Systems (UV, RI, CAD detection)||Lyophilizers|
|GC Systems||Semi-solid Processing Equipment|
|Differential Scanning Calorimeter (DSC)||Microfluidizer|
|Freeze Drying Microscope||Dynomill|
|Dissolution Testing Apparatuses||Pilot Scale Ampule Filling Machine|
|USP Particle Counter|
|Particle Size Distribution Analyzer|
|Karl Fisher Titrator|
|Electrophoresis, IEF, Other Bioanalytical Equipment|
|Molecule/Therapeutic Area||Dosage Form||Stage|
|Cyclosporin||Sterile opthalmic solution||Preclinical development|
|Antidepressant||Oral solution||505(b)2, Clinical development|
|Anti-inflammatory/Antibiotic||Sterile opthalmic suspension||Preclinical development|
|Oncology||Sterile lyophilized product||505(b)2, Preclinical development|
|Oncology||Sterile nanosuspension||Preclinical development|
|Emergency Treatment||Oral solid||Clinical development|